Skip to main content
Top
Published in: Clinical and Translational Allergy 1/2011

Open Access 01-12-2011 | Research

Difference in symptom severity between early and late grass pollen season in patients with seasonal allergic rhinitis

Authors: Letty A de Weger, Thijs Beerthuizen, Jeannette M Gast-Strookman, Dirk T van der Plas, Ingrid Terreehorst, Pieter S Hiemstra, Jacob K Sont

Published in: Clinical and Translational Allergy | Issue 1/2011

Login to get access

Abstract

Background

For the development of forecasts for seasonal allergic rhinitis symptoms, it is essential to understand the relationship between grass pollen concentrations and the symptoms of grass pollen allergic patients.

Objective

The aim of this study was to delineate this relationship between seasonal allergic rhinitis symptoms and grass pollen concentrations in the Netherlands.

Methods

Grass pollen allergic patients (n = 80 [2007] - 84 [2008]) were enrolled into the study. They were asked to enter their seasonal allergic rhinitis symptoms (runny nose, sneezing, blocked nose, post nasal drip, and eye symptoms) daily on a scale from 0 to 3 to the study centre either by short message service (SMS) or by internet from May-July 2007 and April-July 2008. Daily pollen counts were used to define the early and the late grass pollen season as the period 'before and during' respectively 'after' the first grass pollen peak (more than 150 pollen/m3).

Results

At similar grass pollen concentrations, the daily mean of the individual maximum symptom scores reported in the early season were higher as compared to that reported in the late season [differences of -0.41 (2007) and -0.30 (2008)]. This difference could not be explained by medication use by the patients nor by co-sensitization to birch.

Conclusions

We conclude that seasonal allergic rhinitis symptoms at similar grass pollen concentrations are more severe in the early flowering season as compared to those in the late flowering season. This finding is not only relevant for development of forecasts for seasonal allergic rhinitis symptoms but also for understanding symptom development and planning and analysis of clinical studies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Walter CG, Merk H: GA(2) LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010, 65: 1525-1530. 10.1111/j.1398-9995.2010.02474.x.CrossRefPubMed Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Walter CG, Merk H: GA(2) LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010, 65: 1525-1530. 10.1111/j.1398-9995.2010.02474.x.CrossRefPubMed
2.
go back to reference Katelaris CH, Bielory L: Evidence-based study design in ocular allergy trials. Curr Opin Allergy Clin Immunol. 2008, 8: 484-488. 10.1097/ACI.0b013e32830e6b29.CrossRefPubMed Katelaris CH, Bielory L: Evidence-based study design in ocular allergy trials. Curr Opin Allergy Clin Immunol. 2008, 8: 484-488. 10.1097/ACI.0b013e32830e6b29.CrossRefPubMed
3.
go back to reference Burbach GJ, Heinzerling LM, Edenharter G, Bachert C, Bindslev-Jensen C, Bonini S, Bousquet J, Bousquet-Rouanet L, Bousquet PJ, Bresciani M, Bruno A, Canonica GW, Darsow U, Demoly P, Durham S, Fokkens WJ, Giavi S, Gjomarkaj M, Gramiccioni C, Haahtela T, Kowalski ML, Magyar P, Murakoz G, Orosz M, Papadopoulos NG, Rohnelt C, Stingl G, Todo-Bom A, von Mutius E, Wiesner A, Wohrl S, Zuberbier T: GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy. 2009, 64: 1507-1515. 10.1111/j.1398-9995.2009.02089.x.CrossRefPubMed Burbach GJ, Heinzerling LM, Edenharter G, Bachert C, Bindslev-Jensen C, Bonini S, Bousquet J, Bousquet-Rouanet L, Bousquet PJ, Bresciani M, Bruno A, Canonica GW, Darsow U, Demoly P, Durham S, Fokkens WJ, Giavi S, Gjomarkaj M, Gramiccioni C, Haahtela T, Kowalski ML, Magyar P, Murakoz G, Orosz M, Papadopoulos NG, Rohnelt C, Stingl G, Todo-Bom A, von Mutius E, Wiesner A, Wohrl S, Zuberbier T: GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy. 2009, 64: 1507-1515. 10.1111/j.1398-9995.2009.02089.x.CrossRefPubMed
4.
go back to reference D'Amato G, Cecchi L, Bonini S, Nunes C, Annesi-Maesano I, Behrendt H, Liccardi G, Popov T, Van CP: Allergenic pollen and pollen allergy in Europe. Allergy. 2007, 62: 976-990. 10.1111/j.1398-9995.2007.01393.x.CrossRefPubMed D'Amato G, Cecchi L, Bonini S, Nunes C, Annesi-Maesano I, Behrendt H, Liccardi G, Popov T, Van CP: Allergenic pollen and pollen allergy in Europe. Allergy. 2007, 62: 976-990. 10.1111/j.1398-9995.2007.01393.x.CrossRefPubMed
5.
go back to reference Andersson K, Lidholm J: Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol. 2003, 130: 87-107. 10.1159/000069013.CrossRefPubMed Andersson K, Lidholm J: Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol. 2003, 130: 87-107. 10.1159/000069013.CrossRefPubMed
6.
go back to reference Spieksma FT: Daily hay fever forecast in the Netherlands. Radio broadcasting of the expected influence of the weather or subjective complaints of hay fever sufferers. Allergy. 1980, 35: 593-603. 10.1111/j.1398-9995.1980.tb01810.x.CrossRefPubMed Spieksma FT: Daily hay fever forecast in the Netherlands. Radio broadcasting of the expected influence of the weather or subjective complaints of hay fever sufferers. Allergy. 1980, 35: 593-603. 10.1111/j.1398-9995.1980.tb01810.x.CrossRefPubMed
7.
go back to reference Viander M, Koivikko A: The seasonal symptoms of hyposensitized and untreated hay fever patients in relation to birch pollen counts: correlations with nasal sensitivity, prick tests and RAST. Clin Allergy. 1978, 8: 387-396. 10.1111/j.1365-2222.1978.tb00474.x.CrossRefPubMed Viander M, Koivikko A: The seasonal symptoms of hyposensitized and untreated hay fever patients in relation to birch pollen counts: correlations with nasal sensitivity, prick tests and RAST. Clin Allergy. 1978, 8: 387-396. 10.1111/j.1365-2222.1978.tb00474.x.CrossRefPubMed
8.
go back to reference Van Hoorn JG, van Dishoeck H: Content of pollen and spores in the air; meteorological conditions and hay-fever complaints. Pract Otorhinolaryngol (Basel). 1958, 20: 14-25. Van Hoorn JG, van Dishoeck H: Content of pollen and spores in the air; meteorological conditions and hay-fever complaints. Pract Otorhinolaryngol (Basel). 1958, 20: 14-25.
9.
go back to reference Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaument O, Le Gall M: Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009, 123: 160-166. 10.1016/j.jaci.2008.10.009.CrossRefPubMed Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaument O, Le Gall M: Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009, 123: 160-166. 10.1016/j.jaci.2008.10.009.CrossRefPubMed
10.
go back to reference Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999, 341: 468-475. 10.1056/NEJM199908123410702.CrossRefPubMed Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999, 341: 468-475. 10.1056/NEJM199908123410702.CrossRefPubMed
11.
go back to reference Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, Passalacqua G, Potter P, Valovirta E: Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007, 62: 317-324. 10.1111/j.1398-9995.2006.01312.x.CrossRefPubMed Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, Passalacqua G, Potter P, Valovirta E: Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007, 62: 317-324. 10.1111/j.1398-9995.2006.01312.x.CrossRefPubMed
12.
go back to reference Akerlund A, Andersson M, Leflein J, Lildholdt T, Mygind N: Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. J Allergy Clin Immunol. 2005, 115: S460-S482. 10.1016/j.jaci.2004.12.016.CrossRefPubMed Akerlund A, Andersson M, Leflein J, Lildholdt T, Mygind N: Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. J Allergy Clin Immunol. 2005, 115: S460-S482. 10.1016/j.jaci.2004.12.016.CrossRefPubMed
13.
go back to reference Connell JT: Quantitative intranasal pollen challenge. II. Effect of daily pollen challenge, environmental pollen exposure, and placebo challenge on the nasal membrane. J Allergy. 1968, 41: 123-139. 10.1016/0021-8707(68)90053-1.CrossRefPubMed Connell JT: Quantitative intranasal pollen challenge. II. Effect of daily pollen challenge, environmental pollen exposure, and placebo challenge on the nasal membrane. J Allergy. 1968, 41: 123-139. 10.1016/0021-8707(68)90053-1.CrossRefPubMed
14.
go back to reference de Bruin-Weller MS, Weller FR, De Monchy JG: Repeated allergen challenge as a new research model for studying allergic reactions. Clin Exp Allergy. 1999, 29: 159-165. 10.1046/j.1365-2222.1999.00434.x.CrossRefPubMed de Bruin-Weller MS, Weller FR, De Monchy JG: Repeated allergen challenge as a new research model for studying allergic reactions. Clin Exp Allergy. 1999, 29: 159-165. 10.1046/j.1365-2222.1999.00434.x.CrossRefPubMed
15.
go back to reference Frenz DA: Interpreting atmospheric pollen counts for use in clinical allergy: allergic symptomology. Ann Allergy Asthma Immunol. 2001, 86: 150-7. 10.1016/S1081-1206(10)62683-X.CrossRefPubMed Frenz DA: Interpreting atmospheric pollen counts for use in clinical allergy: allergic symptomology. Ann Allergy Asthma Immunol. 2001, 86: 150-7. 10.1016/S1081-1206(10)62683-X.CrossRefPubMed
16.
go back to reference Grammer L, Wiggins C, Shaughnessy MA, Chmiel J: Absence of nasal priming as measured by rhinitis symptom scores of ragweed allergic patients during seasonal exposure to ragweed pollen. Allergy Proc. 1990, 11: 243-246. 10.2500/108854190778879819.CrossRefPubMed Grammer L, Wiggins C, Shaughnessy MA, Chmiel J: Absence of nasal priming as measured by rhinitis symptom scores of ragweed allergic patients during seasonal exposure to ragweed pollen. Allergy Proc. 1990, 11: 243-246. 10.2500/108854190778879819.CrossRefPubMed
17.
go back to reference Rosenthal RR, Norman PS, Summer WR: Bronchoprovocation: effect on priming and desensitization phenomenon in the lung. J Allergy Clin Immunol. 1975, 56: 338-346. 10.1016/0091-6749(75)90127-X.CrossRefPubMed Rosenthal RR, Norman PS, Summer WR: Bronchoprovocation: effect on priming and desensitization phenomenon in the lung. J Allergy Clin Immunol. 1975, 56: 338-346. 10.1016/0091-6749(75)90127-X.CrossRefPubMed
18.
go back to reference Wachs M, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM: Observations on the pathogenesis of nasal priming. J Allergy Clin Immunol. 1989, 84: 492-501. 10.1016/0091-6749(89)90362-X.CrossRefPubMed Wachs M, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM: Observations on the pathogenesis of nasal priming. J Allergy Clin Immunol. 1989, 84: 492-501. 10.1016/0091-6749(89)90362-X.CrossRefPubMed
19.
go back to reference Jutel M, Akdis M, Blaser K, Akdis CA: Mechanisms of allergen specific immunotherapy--T-cell tolerance and more. Allergy. 2006, 61: 796-807. 10.1111/j.1398-9995.2006.01175.x.CrossRefPubMed Jutel M, Akdis M, Blaser K, Akdis CA: Mechanisms of allergen specific immunotherapy--T-cell tolerance and more. Allergy. 2006, 61: 796-807. 10.1111/j.1398-9995.2006.01175.x.CrossRefPubMed
20.
go back to reference Nouri-Aria KT: Foxp3 expressing regulatory T-cells in allergic disease. Adv Exp Med Biol. 2009, 665: 180-194. 10.1007/978-1-4419-1599-3_14.CrossRefPubMed Nouri-Aria KT: Foxp3 expressing regulatory T-cells in allergic disease. Adv Exp Med Biol. 2009, 665: 180-194. 10.1007/978-1-4419-1599-3_14.CrossRefPubMed
21.
go back to reference Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT: Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008, 121: 1467-72. 10.1016/j.jaci.2008.03.013.CrossRefPubMed Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT: Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008, 121: 1467-72. 10.1016/j.jaci.2008.03.013.CrossRefPubMed
Metadata
Title
Difference in symptom severity between early and late grass pollen season in patients with seasonal allergic rhinitis
Authors
Letty A de Weger
Thijs Beerthuizen
Jeannette M Gast-Strookman
Dirk T van der Plas
Ingrid Terreehorst
Pieter S Hiemstra
Jacob K Sont
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Clinical and Translational Allergy / Issue 1/2011
Electronic ISSN: 2045-7022
DOI
https://doi.org/10.1186/2045-7022-1-18

Other articles of this Issue 1/2011

Clinical and Translational Allergy 1/2011 Go to the issue